Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662448 · ClinicalTrials.gov registry record · NA
Repetitive Transorbital Alternating Current Stimulation for Optic Neuropathies
A NA study of Optic Neuropathy, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06662448 is a NA study of Optic Neuropathy that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06662448, a NA study of Optic Neuropathy, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the efficacy and feasibility of an intervention protocol for home-based repetitive transorbital alternating current stimulation (rtACS) for the treatment of visual impairment in people with optic neuropathy. The primary aims are to evaluate the effectiveness of home-based rtACS to ameliorate the progressive effects of vision loss functionally in the eye and the visual pathway, and in regard to people's independence (i.e., functional ability).
Conditions Studied
Interventions
- DEVICE SAVIR Alpha Synch mobile (SASm)
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2029-05-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06662448
The ClinicalTrials.gov registry entry for NCT06662448 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Optic Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which SAVIR Alpha Synch mobile (SASm) is the first listed.
NCT06662448 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06662448 about?
NCT06662448 is a clinical study titled "Repetitive Transorbital Alternating Current Stimulation for Optic Neuropathies". The purpose of this study is to test the efficacy and feasibility of an intervention protocol for home-based repetitive transorbital alternating current stimulation (rtACS) for the treatment of visual impairment in people with optic neuropathy. The primary aims are to evaluate the effectiveness of h...
What is the current status of trial NCT06662448?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-11-18. Estimated completion is 2029-05-18.
What conditions does trial NCT06662448 study?
This clinical trial studies the following conditions: Optic Neuropathy.
What interventions are being tested in trial NCT06662448?
The interventions under investigation include: SAVIR Alpha Synch mobile (SASm) (DEVICE).
Who is sponsoring clinical trial NCT06662448?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06662448 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Optic Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.